Constance Shiridzinomwa

Papers

2

Total Citations

346

H-Index

2

About

Constance Shiridzinomwa is a leading surgical oncologist whose work is redefining the standard of care for bladder cancer treatment. Her primary research focuses on the comparative effectiveness and health economics of robotic versus open radical cystectomy, a major surgical procedure for muscle-invasive disease. Dr. Shiridzinomwa’s landmark 2022 study, cited over 320 times, provided pivotal evidence that robot-assisted radical cystectomy with intracorporeal urinary diversion significantly reduces 90-day morbidity compared to open surgery, challenging long-held surgical norms. Building on this, her 2023 cost-effectiveness analysis demonstrated that the robotic approach offers superior value to healthcare payers, addressing critical questions of resource allocation in oncology. By rigorously combining clinical outcomes with economic modeling, she has equipped surgeons and policymakers with the data needed to adopt less invasive techniques without compromising oncologic safety. Her work has been instrumental in shifting the global conversation around surgical innovation, proving that what is better for the patient can also be more efficient for the system.

Research Focus

Key Achievements

2
H-Index
2
Papers
346
Total Citations
173
Avg Citations/Paper
🏆 Most Cited Paper
Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer
320 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 70

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 15 days ago